Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.
about
East meets West: ethnic differences in prostate cancer epidemiology between East Asians and CaucasiansBenefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection ProgramDistinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells.Landmarks in prostate cancer screening.Prostate-specific antigen-based prostate cancer screening: Past and future.Prediction of cancer incidence in Tyrol/Austria for year of diagnosis 2020.The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer.The ONCOTYROL Prostate Cancer Outcome and Policy Model: Effect of Prevalence Assumptions on the Benefit-Harm Balance of Screening.Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis.Inhibition of Nox4-dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal-mediated pro-tumorigenic interactions.Time trends in prostate cancer mortality according to major geographic regions of Brazil: an analysis of three decades.Prostate cancer screening: what can we learn from randomised trials?Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).
P2860
Q26827438-626D250C-AC6E-4C09-A8F4-D914DB8B33BFQ33836709-A39BC2C2-2DA4-41CD-AF14-F3AAC2F9C78AQ35720012-66EE3490-8009-42D0-9579-B03AA86E35D5Q36848024-E60E97EC-DA5B-4F3F-A319-9C12C2A1A82FQ37105704-10E6646F-2264-493B-A0D4-5514068B6683Q38050464-5A83E6D1-EF0C-4100-A813-2E1AA5D641A6Q38408501-F8EA6B0B-A5AD-48D3-8177-CB57D2C6D3B1Q39134026-2EB34C6B-A7B3-41DA-88F5-A1600AEBB2C7Q39286062-F7F9D989-776C-4CE2-AFBB-776B42CD4A39Q40936828-A9C15656-BBAB-4CEE-BC8D-64A31BF5B57BQ41071424-1EE0D86A-D1D0-4278-80E0-3F465E3CE147Q50020648-084DDE1E-7AE8-4568-94F3-2FF22E20E5CBQ51243819-76BC0FBA-E951-411B-8754-E57F08655521Q52624234-46ED445E-2E79-420F-8610-9C587367C6FBQ53734447-97900C60-EC75-44D3-A2D1-F11595A6E3DC
P2860
Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Prostate-specific antigen test ...... ith mortality data up to 2008.
@ast
Prostate-specific antigen test ...... ith mortality data up to 2008.
@en
type
label
Prostate-specific antigen test ...... ith mortality data up to 2008.
@ast
Prostate-specific antigen test ...... ith mortality data up to 2008.
@en
prefLabel
Prostate-specific antigen test ...... ith mortality data up to 2008.
@ast
Prostate-specific antigen test ...... ith mortality data up to 2008.
@en
P2093
P2860
P1476
Prostate-specific antigen test ...... with mortality data up to 2008
@en
P2093
Ferdinand Frauscher
Georg Bartsch
Georg Schäfer
Harald Schennach
Helmut Klocker
Jasmin Bektic
Willi Oberaigner
Wolfgang Horninger
P2860
P2888
P356
10.1007/S00038-011-0266-4
P50
P577
2011-06-17T00:00:00Z
P5875
P6179
1036663341